Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

L. Molife · SciRah

Researcher profile · Semantic Scholar

L. Molife

Share profile

L. Molife — researcher profile on SciRah

h-index: 36
Works: 160
Citations: 6,216

Most-cited papers

Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial.
T. Powles, E. Plimack, D. Soulières, T. Waddell +16 more
2020The Lancet Oncology601 citations
Semantic Scholar
Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor
L. Barber, S. Sandhu, Lina Chen, James Campbell +12 more
2013Journal of Pathology343 citations
Semantic Scholar
Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety.
U. Matulonis, R. Penson, S. Domchek, B. Kaufman +9 more
2016Annals of Oncology162 citations Open access
Semantic Scholar
Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors
L. Molife, Li Yan, Joanna Vitfell-Rasmussen, Adriane M Zernhelt +11 more
2014Journal of Hematology & Oncology161 citations Open access
Semantic Scholar
Cancer therapeutics: Targeting the apoptotic pathway.
K. Khan, M. Blanco-Codesido, L. Molife
2014Critical reviews in oncology/hematology148 citations
Semantic Scholar
Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study.
E. Plimack, T. Powles, V. Stus, R. Gafanov +17 more
2023European Urology146 citations
Semantic Scholar
An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib
J. Mateo, Victor Moreno, Avinash Gupta, S. Kaye +14 more
2016Targeted oncology132 citations Open access
Semantic Scholar
Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426.
B. Rini, E. Plimack, V. Stus, T. Waddell +16 more
2021Journal of Clinical Oncology85 citations
Semantic Scholar
A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours
R. Wilson, T. J. Evans, M. Middleton, L. Molife +7 more
2017British Journal of Cancer73 citations Open access
Semantic Scholar
Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426.
B. Rini, E. Plimack, V. Stus, R. Gafanov +16 more
2023Journal of Clinical Oncology65 citations
Semantic Scholar
Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer.
Shahneen K. Sandhu, A. Omlin, Lucy Hylands, S. Miranda +20 more
2013Annals of Oncology64 citations Open access
Semantic Scholar
Hyperglycemia and Phosphatidylinositol 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) Inhibitors in Phase I Trials: Incidence, Predictive Factors, and Management.
K. Khan, M. Wong, K. Rihawi, S. Bodla +3 more
2016The Oncologist60 citations Open access
Semantic Scholar
Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426.
E. Plimack, B. Rini, V. Stus, R. Gafanov +16 more
2020Journal of Clinical Oncology54 citations
Semantic Scholar
Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours
R. Plummer, H. Swaisland, K. Leunen, C. V. van Herpen +11 more
2015Cancer Chemotherapy and Pharmacology53 citations
Semantic Scholar
First-in-human, Pharmacokinetic and Pharmacodynamic Phase I Study of Resminostat, an Oral Histone Deacetylase Inhibitor, in Patients with Advanced Solid Tumors
A. Brunetto, J. Ang, R. Lal, D. Olmos +10 more
2013Clinical Cancer Research52 citations Open access
Semantic Scholar
Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies.
L. Dirix, H. Swaisland, H. Verheul, S. Rottey +14 more
2016Clinical Therapeutics49 citations Open access
Semantic Scholar
Abstract CT103: Clinical safety and efficacy of pembrolizumab (MK-3475) in patients with malignant pleural mesothelioma: Preliminary results from KEYNOTE-028
E. Alley, L. Molife, A. Santoro, K. Beckey +4 more
201544 citations
Semantic Scholar
Antitumor activity of ipatasertib combined with chemotherapy: results from a phase Ib study in solid tumors.
S. Isakoff, J. Tabernero, L. Molife, J. Soria +17 more
2020Annals of Oncology38 citations Open access
Semantic Scholar
Higher risk of infections with PI3K-AKT-mTOR pathway inhibitors in patients with advanced solid tumors on Phase I clinical trials
S. Rafii, D. Roda, E. Geuna, B. Jímenez +7 more
2015Clinical Cancer Research35 citations Open access
Semantic Scholar
Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma.
J. Bedke, B. Rini, E. Plimack, V. Stus +17 more
2022European Urology33 citations
Semantic Scholar
Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer.
L. Molife, A. Omlin, Rob J. Jones, V. Karavasilis +15 more
2014Future Oncology32 citations
Semantic Scholar
Complications of hyperglycaemia with PI3K–AKT–mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials
E. Geuna, D. Roda, S. Rafii, B. Jímenez +8 more
2015British Journal of Cancer31 citations Open access
Semantic Scholar
Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and Renal Impairment
C. Rolfo, J. de Vos-Geelen, N. Isambert, L. Molife +12 more
2019Clinical Pharmacokinetics30 citations Open access
Semantic Scholar
Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer
S. Rafii, C. Gourley, Rajiv Kumar, E. Geuna +13 more
2017OncoTarget28 citations Open access
Semantic Scholar
1303PDNivolumab in previously treated patients with metastatic squamous NSCLC: Results of a European single-arm, phase 2 trial (CheckMate 171) including patients aged ≥70 years and with poor performance status
S. Popat, A. Ardizzoni, T. Ciuleanu, M. C. Dols +16 more
201728 citations Open access
Semantic Scholar
A Phase I, Dose-Escalation Study of the Multitargeted Receptor Tyrosine Kinase Inhibitor, Golvatinib, in Patients with Advanced Solid Tumors
L. Molife, E. Dean, M. Blanco-Codesido, M. Krebs +9 more
2014Clinical Cancer Research28 citations Open access
Semantic Scholar
A Phase I study of the safety, pharmacokinetics and efficacy of navitoclax plus docetaxel in patients with advanced solid tumors.
M. Puglisi, L. Molife, M. D. de Jonge, K. Khan +8 more
2021Future Oncology27 citations Open access
Semantic Scholar
Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and mild or moderate hepatic impairment
C. Rolfo, N. Isambert, Antoine Italiano, L. Molife +13 more
2020British Journal of Clinical Pharmacology22 citations Open access
Semantic Scholar
Results of stage 1 of the oparatic trial: A phase I study of olaparib in combination with temozolomide in patients with relapsed glioblastoma.
A. Chalmers, A. Jackson, H. Swaisland, W. Stewart +4 more
201421 citations
Semantic Scholar
Administration of continuous/intermittent olaparib in ovarian cancer patients with a germline BRCA1/2 mutation to determine an optimal dosing schedule for the tablet formulation
J. Mateo, M. Friedlander, C. Sessa, K. Leunen +6 more
201321 citations
Semantic Scholar
Phase I trial outcomes in older patients with advanced solid tumours
K. Khan, T. Yap, A. Ring, L. Molife +8 more
2016British Journal of Cancer20 citations Open access
Semantic Scholar
Abstract PR14: Phase I trial of first-in-class ataxia telangiectasia-mutated and Rad3-related (ATR) inhibitor VX-970 as monotherapy (mono) or in combination with carboplatin (CP) in advanced cancer patients (pts) with preliminary evidence of target modulation and antitumor activity
T. Yap, M. D. De Miguel Luken, Brent O'Carrigan, D. Roda +18 more
201518 citations
Semantic Scholar
Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors
L. Molife, S. Rudman, S. Alam, D. Tan +9 more
2013Cancer Chemotherapy and Pharmacology18 citations
Semantic Scholar
Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours
T. Jeffry Evans, E. Dean, L. Molife, Juanita Lopez +10 more
2019British Journal of Cancer16 citations Open access
Semantic Scholar
Abstract CT323: Accelerated phase I trial of two schedules of the combination of the PARP inhibitor olaparib and AKT inhibitor AZD5363 using a novel intrapatient dose escalation design in advanced cancer patients
V. Michalarea, D. Lorente, Juanita Lopez, S. Carreira +18 more
201514 citations
Semantic Scholar
A phase I study of oral rucaparib in combination with carboplatin.
L. Molife, P. Roxburgh, R. Wilson, Avinash Gupta +15 more
201313 citations Open access
Semantic Scholar
The KRAS G12C inhibitor MK-1084 for KRAS G12C–mutated advanced colorectal cancer (CRC): Results from KANDLELIT-001.
I. Lugowska, Matteo Simonelli, Junli Xue, A. Sacher +16 more
2025Journal of Clinical Oncology12 citations Open access
Semantic Scholar
Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours
R. Plummer, H. Verheul, F. D. de Vos, K. Leunen +15 more
2018Advances in Therapy12 citations Open access
Semantic Scholar
Biomarker analysis of the phase 3 KEYNOTE-426 study of pembrolizumab (P) plus axitinib (A) versus sunitinib (S) for advanced renal cell carcinoma (RCC).
B. Rini, E. Plimack, V. Stus, R. Gafanov +16 more
2024Journal of Clinical Oncology11 citations Open access
Semantic Scholar
Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials.
A. George, R. Kristeleit, S. Rafii, C. Michie +13 more
2017European Journal of Cancer11 citations Open access
Semantic Scholar
Final results of the phase I trial of niraparib (MK4827), a poly(ADP)ribose polymerase (PARP) inhibitor incorporating proof of concept biomarker studies and expansion cohorts involving BRCA1/2 mutation carriers, sporadic ovarian, and castration resistant prostate cancer (CRPC).
C. Michie, S. Sandhu, W. Schelman, L. Molife +8 more
201311 citations
Semantic Scholar
MK-1084 for KRAS G12C-mutated (mut) metastatic non–small-cell lung cancer (mNSCLC): Results from KANDLELIT-001.
A. Sacher, M. Şendur, Anastasios Stathis, Maya Gottfried +15 more
2025Journal of Clinical Oncology10 citations
Semantic Scholar
High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy
R. Pérez-López, D. Roda, B. Jímenez, Jessica Brown +10 more
2017OncoTarget10 citations Open access
Semantic Scholar
Abstract A218: Pharmacokinetics of orally administered rucaparib in patients with advanced solid tumors.
G. Shapiro, R. Kristeleit, M. Middleton, H. Burris +13 more
201310 citations
Semantic Scholar
Pharmacokinetics of orally administered rucaparib in patients with advanced solid tumors.
G. Shapiro, R. Kristeleit, M. Middleton, H. Burris +13 more
201310 citations
Semantic Scholar
Outcomes for patients in the pembrolizumab+axitinib arm with advanced renal cell carcinoma (RCC) who completed two years of treatment in the phase III KEYNOTE-426 study.
E. Plimack, T. Powles, J. Bedke, F. Pouliot +16 more
20219 citations
Semantic Scholar
Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours
R. Kristeleit, J. Evans, L. Molife, N. Tunariu +21 more
2020British Journal of Cancer9 citations Open access
Semantic Scholar
Phase I Trials in Patients with Relapsed, Advanced Upper Gastrointestinal Carcinomas – Experience in a Specialist Unit
K. Khan, J. Ang, N. Starling, F. Sclafani +7 more
2014Gastric Cancer8 citations Open access
Semantic Scholar
First-line pembrolizumab-axitinib versus sunitinib in metastatic RCC: subgroup analysis of patients enrolled in the phase 3 KEYNOTE-426 in Eastern Asia
Hsiao-Jen Chung, C. Kondoh, W. K. Bae, S. Tamada +14 more
2025Japanese Journal of Clinical Oncology7 citations Open access
Semantic Scholar
Abstract A54: First-in-human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640 as monotherapy or in combination - final results of dose escalation
A. Brenner, J. Infante, M. Patel, H. Arkenau +14 more
20157 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

J. de Bono×14
Invite
J. de Bono — researcher profile on SciRah
R. Plummer×10
Invite
R. Plummer — researcher profile on SciRah
T. Powles×9
Invite
T. Powles — researcher profile on SciRah
U. Banerji×9
Invite
U. Banerji — researcher profile on SciRah

×8

Invite

V. Stus — researcher profile on SciRah

Invite

R. Gafanov — researcher profile on SciRah

Invite

S. Kaye — researcher profile on SciRah

Invite

T. Yap — researcher profile on SciRah

R. Kristeleit×8

Invite

R. Kristeleit — researcher profile on SciRah

Invite

D. Nosov — researcher profile on SciRah

Invite

F. Pouliot — researcher profile on SciRah

D. Borchiellini×7

Invite

D. Borchiellini — researcher profile on SciRah